MedTrace Logo

Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer

NCT07720167 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2026-07-22

No results posted yet for this study

Summary

The study will investigate the role of cemiplimab in combination with platinum doublet chemotherapy in stage I resectable non-small cell lung cancer (NSCLC). Sub-4cm NSCLC tumors are highly lethal malignancies, yet no therapies are used in these patients to improve chances of survival with surgery alone. Here will be examined the ability of 3 cycles of cemiplimab-chemotherapy to induce pathologic complete responses to treatment.

Conditions

Interventions

DRUG

Cemiplimab

administered at a dose of 350 mg as an intravenous infusion over 30 minutes

DRUG

Carboplatin + Pemetrexed/Paclitaxel

every 21 days for three cycles if not using cisplatin

DRUG

Cisplatin

every 21 days for three cycles if not using carboplatin and pemetrexed/paclitaxel

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-01
Primary Completion
2029-11-01
Completion
2030-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07720167 on ClinicalTrials.gov